Professor Geoff McCaughan, head of Centenary’s liver program.
Prof Geoff McCaughan has an editorial in today’s Medical Journal of Australia saying that hepatitis C therapy is undergoing radical and rapid change. He predicts that within five years we will have short-duration anti-hepatitis C therapy with minimal side-effects and cure rates above 90%.
The burden of hepatitis C (HCV) associated liver failure and liver cancer is rising so these new drugs are just in time.